{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T09:44:06Z","timestamp":1782812646524,"version":"3.54.5"},"reference-count":208,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Ribonucleic acid-based vaccines have emerged as one of the most significant advances in modern vaccine development, demonstrating remarkable clinical success and enabling rapid responses to emerging infectious diseases. Despite their therapeutic potential, the development of these vaccines remains challenging because of the inherent instability of ribonucleic acid molecules, their susceptibility to degradation, and the complexity of formulation design. Ensuring product quality, stability, and biological performance therefore requires comprehensive analytical characterization throughout development, manufacturing, storage, and quality control. This review provides a comprehensive overview of current analytical strategies used to evaluate ribonucleic acid-based vaccine formulations. Key analytical approaches for assessing molecular integrity, purity, encapsulation efficiency, particle morphology, size distribution, surface characteristics, structural attributes, and biological potency are discussed. The review also examines the influence of formulation composition, lipid nanoparticle design, manufacturing processes, and storage conditions on vaccine stability and performance. In addition, major degradation pathways, critical quality attributes, and analytical challenges associated with quality assessment are highlighted. Furthermore, current regulatory considerations and limitations of existing analytical methodologies are discussed, particularly the challenges associated with establishing robust relationships between physicochemical properties and biological efficacy. The review emphasizes the importance of integrated multi-method analytical approaches for comprehensive characterization and quality assurance. Continued advances in analytical technologies and standardization efforts will be essential for supporting the development of safe, effective, and stable ribonucleic acid-based vaccines and for facilitating their broader pharmaceutical applications.<\/jats:p>","DOI":"10.3390\/pharmaceutics18070790","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:26:15Z","timestamp":1782807975000},"page":"790","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical Characterization and Stability Assessment of RNA-Based Vaccines"],"prefix":"10.3390","volume":"18","author":[{"given":"Hadi M.","family":"Alasmari","sequence":"first","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouq F.","family":"Alghannam","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan A.","family":"Al-Moammar","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimah K.","family":"Alrabiah","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seham S.","family":"Al-Harthy","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam J.","family":"Alyamani","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami A.","family":"Alyahya","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alkhrayef","sequence":"additional","affiliation":[{"name":"Disability Research Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohannad","family":"Fallatah","sequence":"additional","affiliation":[{"name":"Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 12354, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiyah","family":"Al-Khaldi","sequence":"additional","affiliation":[{"name":"Applied Genomics Technologies Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-3724","authenticated-orcid":false,"given":"Abdulmalek T.","family":"Algarni","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4809-9743","authenticated-orcid":false,"given":"Yahya F.","family":"Jamous","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad M.","family":"Aldossary","sequence":"additional","affiliation":[{"name":"Wellness and Preventive Medicine Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Tani, H. (2024). Recent advances and prospects in RNA drug development. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212284"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Camperi, J., Chatla, K., Freund, E., Galan, C., Lippold, S., and Guilbaud, A. (2025). Current analytical strategies for mRNA-based therapeutics. Molecules, 30.","DOI":"10.3390\/molecules30071629"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Makkar, S.K. (2025). Advances in RNA-based therapeutics: Current breakthroughs, clinical translation, and future perspectives. Front. Genet., 16.","DOI":"10.3389\/fgene.2025.1675209"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114000","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Magoola, M., and Niazi, S.K. (2025). Current progress and future perspectives of RNA-based cancer vaccines: A 2025 update. Cancers, 17.","DOI":"10.3390\/cancers17111882"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kornienko, I.V., Aramova, O.Y., Tishchenko, A.A., Rudoy, D.V., and Chikindas, M.L. (2024). RNA stability: A review of the role of structural features and environmental conditions. Molecules, 29.","DOI":"10.3390\/molecules29245978"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.18609\/nai.2024.015","article-title":"Challenges and advances of the stability of mRNA delivery therapeutics","volume":"1","author":"Zhai","year":"2024","journal-title":"Nucleic Acid Insights"},{"key":"ref_11","first-page":"101090","article-title":"The strategies and advances of mRNA translation booster","volume":"20","author":"Shi","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"465724","DOI":"10.1016\/j.chroma.2025.465724","article-title":"Characterisation and analysis of mRNA critical quality attributes using liquid chromatography based methods","volume":"1745","author":"Webb","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W., and Zhang, Y. (2023). Vaccines\u2019 new era\u2014RNA vaccine. Viruses, 15.","DOI":"10.3390\/v15081760"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tong, X., Raffaele, J., Feller, K., Dornadula, G., Devlin, J., Boyd, D., Loughney, J.W., Shanter, J., and Rustandi, R.R. (2024). Correlating stability-indicating biochemical and biophysical characteristics with in vitro cell potency in mRNA LNP vaccine. Vaccines, 12.","DOI":"10.3390\/vaccines12020169"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1038\/s41467-023-38457-x","article-title":"saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern","volume":"14","author":"Komori","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.tibtech.2023.05.007","article-title":"Rise of the RNA machines\u2013self-amplification in mRNA vaccine design","volume":"41","author":"Comes","year":"2023","journal-title":"Trends Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40005-024-00719-1","article-title":"Development of lipid nanoparticle formulation for intramuscular administration of mRNA vaccine against respiratory syncytial virus","volume":"55","author":"Jang","year":"2025","journal-title":"J. Pharm. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"27530","DOI":"10.1039\/D5NR03266K","article-title":"Unraveling the role of PEGylation in the anti-aggregation stability of lipid nanoparticles","volume":"17","author":"Feng","year":"2025","journal-title":"Nanoscale"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"64219","DOI":"10.1021\/acsami.5c17052","article-title":"Effects of serum incubation on lipid nanoparticle PEG shedding, mRNA retention, and membrane interactions","volume":"17","author":"Niederkofler","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, W., Zhang, M., Lv, H., and Yang, C. (2025). Formulation-driven optimization of PEG-lipid content in lipid nanoparticles for enhanced mRNA delivery in vitro and in vivo. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080950"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","article-title":"Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA","volume":"22","author":"Kong","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41551-023-01082-6","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-024-00901-4","article-title":"Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model","volume":"9","author":"England","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00204-024-03912-1","article-title":"Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model","volume":"99","author":"Ahn","year":"2025","journal-title":"Arch. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1039\/D5PM00150A","article-title":"Redefining LNP composition: Phospholipid and sterol-driven modulation of mRNA expression and immune outcomes","volume":"2","author":"Hussain","year":"2025","journal-title":"RSC Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"27977","DOI":"10.1021\/acsnano.5c10648","article-title":"Modulating immunogenicity and reactogenicity in mRNA-lipid nanoparticle vaccines through lipid component optimization","volume":"19","author":"Kawaguchi","year":"2025","journal-title":"ACS Nano"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12951-025-03318-w","article-title":"Influence of salt solution on the physicochemical properties and in vitro\/in vivo expression of mRNA\/LNP","volume":"23","author":"Tang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41541-023-00732-9","article-title":"Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine","volume":"8","author":"Li","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: Examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: Analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s42004-025-01526-x","article-title":"Study on molecular orientation and stratification in RNA-lipid nanoparticles by cryogenic orbitrap secondary ion mass spectrometry","volume":"8","author":"Kotowska","year":"2025","journal-title":"Commun. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"113856","DOI":"10.1016\/j.jconrel.2025.113856","article-title":"Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging","volume":"384","author":"Miller","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1021\/acsnano.2c11904","article-title":"Insights into the structure of comirnaty covid-19 vaccine: A theory on soft, partially bilayer-covered nanoparticles with hydrogen bond-stabilized mRNA\u2013lipid complexes","volume":"17","author":"Szebeni","year":"2023","journal-title":"ACS Nano"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2010.10.025","article-title":"Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles","volume":"403","author":"Crawford","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sanchez-Fernandez, A., Donnelly, K.A., Bolinsson, H., B\u00f6rjesdotter, A.M., R\u00f8nnemoes Bobak, T., Erlendsson, S., Mohammadi-Zerankeshi, M., AboulFotouh, K., Kawelah, M.R., and Herranz-Trillo, F. (2026). Structural heterogeneity in mRNA-LNP subpopulations revealed by AF4-SAXS: Implications for cargo loading and cell transfection. bioRxiv.","DOI":"10.64898\/2026.01.16.699683"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1021\/acs.nanolett.0c01386","article-title":"Deconvoluting lipid nanoparticle structure for messenger RNA delivery","volume":"20","author":"Eygeris","year":"2020","journal-title":"Nano Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101578","DOI":"10.1016\/j.omtm.2025.101578","article-title":"Morphological changes induced by buffer exchange during preparation of mRNA-lipid nanoparticles occur in a stepwise manner as pH is elevated","volume":"33","author":"He","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"122874","DOI":"10.1016\/j.ijpharm.2023.122874","article-title":"Impact of non-ionizable lipids and phase mixing methods on structural properties of lipid nanoparticle formulations","volume":"637","author":"Pratsinis","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1021\/acsnano.5c17445","article-title":"Single-particle multiparametric microscopy reveals structural, size, and payload heterogeneity in mRNA-loaded lipid nanoparticles","volume":"20","author":"Kamanzi","year":"2025","journal-title":"ACS Nano"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19275","DOI":"10.1021\/acs.analchem.5c03299","article-title":"Anion exchange chromatography to determine mRNA encapsulation in lipid nanoparticles","volume":"97","author":"Tsalmpouris","year":"2025","journal-title":"Anal. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"345215","DOI":"10.1016\/j.aca.2026.345215","article-title":"Two-dimensional AEX\u2013IP-RPLC: New insights on mRNA integrity and encapsulation efficiency of mRNA-lipid nanoparticle formulations","volume":"1394","author":"Aebischer","year":"2026","journal-title":"Anal. Chim. Acta"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41434-022-00370-1","article-title":"Taylor dispersion analysis to support lipid-nanoparticle formulations for mRNA vaccines","volume":"30","author":"Malburet","year":"2023","journal-title":"Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1007\/s00216-024-05455-x","article-title":"Development of an advanced separation and characterization platform for mRNA and lipid nanoparticles using multi-detector asymmetrical flow field-flow fractionation","volume":"416","author":"Gao","year":"2024","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Guerrini, G., Mehn, D., Scaccabarozzi, D., Gioria, S., and Calzolai, L. (2024). Analytical ultracentrifugation to assess the quality of LNP-mRNA therapeutics. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115718"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/elps.202200123","article-title":"Two quality and stability indicating imaged CIEF methods for mRNA vaccines","volume":"43","author":"Krebs","year":"2022","journal-title":"Electrophoresis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e02387","DOI":"10.1002\/advs.202502387","article-title":"A comprehensive lateral flow strip assay for on-site mRNA vaccine quality control in decentralized manufacturing","volume":"12","author":"Luo","year":"2025","journal-title":"Adv. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.omtn.2025.102684","article-title":"Analytical approach for identification and mechanistic insights into mRNA-lipid adduct formation","volume":"36","author":"Peronin","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hengelbrock, A., Schmidt, A., and Strube, J. (2023). Formulation of nucleic acids by encapsulation in lipid nanoparticles for continuous production of mRNA. Processes, 11.","DOI":"10.3390\/pr11061718"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43557","DOI":"10.1038\/s41598-025-27563-z","article-title":"Comparative study of analytical methods for assessing mRNA integrity and identification of functional mRNA oligomers","volume":"15","author":"Lardellier","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"9038","DOI":"10.1038\/s41598-023-36193-2","article-title":"Oligonucleotide mapping via mass spectrometry to enable comprehensive primary structure characterization of an mRNA vaccine against SARS-CoV-2","volume":"13","author":"Gau","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_58","unstructured":"Chen, X., Ye, Y., Li, M., Zuo, T., Xie, Z., Ke, Y., Cheng, H., Hong, L., and Liu, Z. (2024). Structural characterization of mRNA lipid nanoparticles in the presence of intrinsic drug-free lipid nanoparticles. bioRxiv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1021\/acs.analchem.1c04778","article-title":"Size and charge characterization of lipid nanoparticles for mRNA vaccines","volume":"94","author":"Malburet","year":"2022","journal-title":"Anal. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"104199","DOI":"10.1016\/j.xphs.2026.104199","article-title":"Developability assessments with four mRNA-LNP vaccine formulations comparing mouse immunogenicity, structural attributes, and stability profiles","volume":"115","author":"Fairlamb","year":"2026","journal-title":"J. Pharm. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Stiving, A.Q., Roose, B.W., Tubbs, C., Haverick, M., Gruber, A., Rustandi, R.R., Kuiper, J., Schombs, M., Schuessler, H., and Li, X. (2024). Enabling functionality and translation fidelity characterization of mRNA-based vaccines with a platform-based, antibody-free mass spectrometry detection approach. bioRxiv.","DOI":"10.1101\/2024.05.14.594137"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-025-01082-4","article-title":"Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection","volume":"10","author":"Stiving","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/elps.70076","article-title":"Concentration approaches for mRNA and mRNA\u2013LNP formulations: Enabling mRNA integrity quantification in low-concentration formulations","volume":"47","author":"Wu","year":"2026","journal-title":"Electrophoresis"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"466387","DOI":"10.1016\/j.chroma.2025.466387","article-title":"Developing a high-throughput capillary gel electrophoresis workflow for mRNA integrity and poly (a) tail analysis","volume":"1761","author":"Su","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"16744","DOI":"10.1038\/s41598-023-43898-x","article-title":"Elucidation of lipid nanoparticle surface structure in mRNA vaccines","volume":"13","author":"Wang","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"113848","DOI":"10.1016\/j.jconrel.2025.113848","article-title":"Direct structural investigation of pH responsiveness in mRNA lipid nanoparticles: Refining paradigms","volume":"384","author":"Wilhelmy","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.xphs.2023.01.007","article-title":"Characterization of BNT162b2 mRNA to evaluate risk of off-target antigen translation","volume":"112","author":"Patel","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1101\/gad.5.11.2108","article-title":"The cap and poly (A) tail function synergistically to regulate mRNA translational efficiency","volume":"5","author":"Gallie","year":"1991","journal-title":"Genes Dev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"108015","DOI":"10.1016\/j.jbc.2024.108015","article-title":"mRNA vaccine sequence and structure design and optimization: Advances and challenges","volume":"301","author":"Jin","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/wrna.52","article-title":"Cap and cap-binding proteins in the control of gene expression","volume":"2","author":"Topisirovic","year":"2011","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102701","DOI":"10.1016\/j.omtn.2025.102701","article-title":"Mind the cap: Detecting degradation impurities in synthetic mRNAs","volume":"36","author":"Nielsen","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chembiol.2023.11.011","article-title":"Targeting cap1 RNA methyltransferases as an antiviral strategy","volume":"31","author":"Tsukamoto","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nature09489","article-title":"2\u2032-O methylation of the viral mRNA cap evades host restriction by IFIT family members","volume":"468","author":"Daffis","year":"2010","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrm2104","article-title":"The highways and byways of mRNA decay","volume":"8","author":"Garneau","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ni.1979","article-title":"Ribose 2\u2032-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5","volume":"12","author":"Habjan","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_78","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl (3\u2032-O-methyl) GpppG and 7-methyl (3\u2032-deoxy) GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0076-6879(07)31011-2","article-title":"Synthesis of anti-reverse cap analogs (ARCAs) and their applications in mRNA translation and stability","volume":"431","author":"Stepinski","year":"2007","journal-title":"Methods Enzymol."},{"key":"ref_80","first-page":"756","article-title":"Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA","volume":"15","author":"Asrani","year":"2018","journal-title":"RNA Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1038\/s41467-024-49508-2","article-title":"Optimizing 5\u2032UTRs for mRNA-delivered gene editing using deep learning","volume":"15","author":"Fedak","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1126\/science.aad9868","article-title":"Translational control by 5\u2032-untranslated regions of eukaryotic mRNAs","volume":"352","author":"Hinnebusch","year":"2016","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1073\/pnas.87.21.8301","article-title":"Downstream secondary structure facilitates recognition of initiator codons by eukaryotic ribosomes","volume":"87","author":"Kozak","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1128\/MCB.19.6.4311","article-title":"Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA","volume":"19","author":"Lai","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","article-title":"Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs identified by cellular library screening","volume":"27","author":"Poleganov","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Muramatsu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an emergency: The role of N1-methylpseudouridine in COVID-19 vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1097-2765(00)80122-7","article-title":"Circularization of mRNA by eukaryotic translation initiation factors","volume":"2","author":"Wells","year":"1998","journal-title":"Mol. Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1134\/S0026893306040133","article-title":"Translational control by the poly (A) binding protein: A check for mRNA integrity","volume":"40","author":"Svitkin","year":"2006","journal-title":"Mol. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"7792","DOI":"10.1093\/nar\/gkae510","article-title":"The impact of mRNA poly (A) tail length on eukaryotic translation stages","volume":"52","author":"Biziaev","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14308","DOI":"10.1021\/acs.analchem.3c02552","article-title":"Liquid chromatography methods for analysis of mRNA poly (A) tail length and heterogeneity","volume":"95","author":"Gilar","year":"2023","journal-title":"Anal. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Boros","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1021\/acs.accounts.1c00521","article-title":"Immunogenicity of in vitro-transcribed RNA","volume":"54","author":"Mu","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14760584.2025.2510335","article-title":"Research progress on immune mechanism and control strategy of dsRNA impurities in mRNA vaccine","volume":"24","author":"Liu","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"114471","DOI":"10.1016\/j.jconrel.2025.114471","article-title":"A systemic evaluation of the effect of dsRNA contamination on mRNA vaccine expression and immunogenicity","volume":"389","author":"Jo","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.omtn.2025.102491","article-title":"Reverse-phase chromatography removes double-stranded RNA, fragments, and residual template to decrease immunogenicity and increase cell potency of mRNA and saRNA","volume":"36","author":"Mencin","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Lenk, R., Kleindienst, W., Szab\u00f3, G.T., Baiersd\u00f6rfer, M., Boros, G., Keller, J.M., Mahiny, A.J., and Vlatkovic, I. (2024). Understanding the impact of in vitro transcription byproducts and contaminants. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1426129"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W., Granzow, M., and Ragg, T. (2006). The RIN: An RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol., 7.","DOI":"10.1186\/1471-2199-7-3"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.analchem.3c05539","article-title":"Comprehensive impurity profiling of mRNA: Evaluating current technologies and advanced analytical techniques","volume":"96","author":"Camperi","year":"2024","journal-title":"Anal. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.slast.2023.06.005","article-title":"Capillary electrophoresis methods for determining the IVT mRNA critical quality attributes of size and purity","volume":"28","author":"Warzak","year":"2023","journal-title":"SLAS Technol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"466625","DOI":"10.1016\/j.chroma.2025.466625","article-title":"Biophysical characterisation of mRNA structure and its impact on integrity analysis by liquid chromatography and capillary gel electrophoresis methods","volume":"1769","author":"Elgohary","year":"2025","journal-title":"J. Chromatogr. A"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1038\/s41467-023-41354-y","article-title":"mRNA vaccine quality analysis using RNA sequencing","volume":"14","author":"Gunter","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/nar\/gkab713","article-title":"TERA-Seq: True end-to-end sequencing of native RNA molecules for transcriptome characterization","volume":"49","author":"Ibrahim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41587-022-01525-6","article-title":"An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts","volume":"41","author":"Dousis","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11033-026-11455-0","article-title":"Process and analytical strategies for the safe production of mRNA vaccines and therapeutics","volume":"53","author":"Nowak","year":"2026","journal-title":"Mol. Biol. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chakravarthi, V.P., and Christenson, L.K. (2025). Wet lab techniques for the functional analysis of circular RNA. Cells, 14.","DOI":"10.3390\/cells14231920"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40164-023-00451-w","article-title":"New insight into circRNAs: Characterization, strategies, and biomedical applications","volume":"12","author":"Feng","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-025-01181-2","article-title":"Establishing correlation between in vitro potency and in vivo immunogenicity for mRNA vaccines","volume":"10","author":"Sanyal","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Feller, K., Nawar, H., Song, L., Abrams, A., Shang, L., Gruber, A., Yun, T., and Li, H.H. (2025). Cell-based relative potency of a respiratory syncytial virus mRNA vaccine correlates with in vivo immunogenicity. Vaccines, 13.","DOI":"10.3390\/vaccines13030326"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: Powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Rahman, M.M., Zhou, N., and Huang, J. (2021). An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo. Vaccines, 9.","DOI":"10.3390\/vaccines9030244"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: Challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1021\/acscentsci.0c01094","article-title":"meCLICK-Seq, a substrate-hijacking and RNA degradation strategy for the study of RNA methylation","volume":"6","author":"Mikutis","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e2409572122","DOI":"10.1073\/pnas.2409572122","article-title":"Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery","volume":"122","author":"Xu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Catenacci, L., Rossi, R., Sechi, F., Buonocore, D., Sorrenti, M., Perteghella, S., Peviani, M., and Bonferoni, M.C. (2024). Effect of lipid nanoparticle physico-chemical properties and composition on their interaction with the immune system. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16121521"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Sato, M., Samaridou, E., Beck-Broichsitter, M., Maeki, M., Kita, S., Tokeshi, M., Maenaka, K., Harashima, H., and Sato, Y. (2025). Examining the impact of storage conditions on the stability of a liquid formulation of mRNA-loaded lipid nanoparticles. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091194"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., and Xu, M. (2023). Research advances on the stability of mRNA vaccines. Viruses, 15.","DOI":"10.3390\/v15030668"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1021\/acschembio.5b00271","article-title":"Divalent metal ions Mg2+ and Ca2+ have distinct effects on protein kinase A activity and regulation","volume":"10","author":"Knape","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Deng, M., Wang, X., Xiong, Z., and Tang, P. (2023). Control of RNA degradation in cell fate decision. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1164546"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Deng, M., Wang, X., and Tang, P. (2025). RNA degradation in pluripotent stem cells: Mechanisms, crosstalk, and fate regulation. Cells, 14.","DOI":"10.3390\/cells14201634"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"13922","DOI":"10.3389\/abp.2025.13922","article-title":"Advancements in single-cell RNA sequencing and spatial transcriptomics: Transforming biomedical research","volume":"72","author":"Birhanu","year":"2025","journal-title":"Acta Biochim. Pol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14760584.2025.2596674","article-title":"Not so cold! Improving the thermostability of mRNA vaccines","volume":"24","author":"Haensler","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Couture-Sen\u00e9cal, J., Tilstra, G., and Khan, O.F. (2024). Engineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability. bioRxiv.","DOI":"10.1101\/2024.08.02.606386"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Jansen, E.M., Ruigrok, M.J.R., Suh, M.S., Ruppel, P.M., Cul, X., Opsomer, L., Sanders, N.N., Frijlink, H.W., and Hinrichs, W.L.J. (2026). Freeze-drying in sucrose followed by cryomilling enables the formulation of sa-mRNA\u2013LNP powders for inhalation. Pharmaceutics, 18.","DOI":"10.3390\/pharmaceutics18010121"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Barrett-Catton, E., Arrigali, E.M., Serban, B.A., Sandau, K.C., and Serban, M.A. (2024). Stability studies of a tetraethyl orthosilicate-based thixotropic drug delivery system. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16111392"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kittle, W.M., Reeves, M.A., Fulkerson, A.E., Hamorsky, K.T., Morris, D.A., Kitterman, K.T., Merchant, M.L., and Matoba, N. (2025). Preclinical long-term stability and forced degradation assessment of EPICERTIN, a mucosal healing biotherapeutic for inflammatory bowel disease. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17020259"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Comanescu, C., and Racovita, R.C. (2024). An overview of degradation strategies for amitriptyline. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073822"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Tsiasioti, A., Zacharis, C.K., Zotou, A.S., and Tzanavaras, P.D. (2020). Study of the oxidative forced degradation of glutathione in its nutraceutical formulations using zone fluidics and green liquid chromatography. Separations, 7.","DOI":"10.3390\/separations7010016"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yang, R., Tee, X.Y., Poornachary, S.K., Simone, E., and Chow, P.S. (2025). Influence of processing and stabilizer selection on microstructure, stability and rheology of emulsion-based semisolid formulations. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091221"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Huang, L., Ni, W., Jia, Y., Zhu, M., Yang, T., Yu, M., and Zhang, J. (2025). Process development for the continuous manufacturing of carbamazepine-nicotinamide co-crystals utilizing hot-melt extrusion technology. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050568"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Pav\u010dnik, L., Locatelli, I., Trdan Lu\u0161in, T., and Ro\u0161kar, R. (2024). Matrixing designs for shelf-life determination of parenteral drug product: A comparative analysis of full and reduced stability testing design. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091117"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Biagini, A., Refrigeri, N., Caglioti, C., Sabbatini, P., Ticconi, S., Ceccarelli, G., Iannitti, R.G., Palazzetti, F., and Fioretti, B. (2024). Accelerated stability testing in food supplements underestimates shelf life prediction of resveratrol with super-Arrhenius behavior. Symmetry, 16.","DOI":"10.3390\/sym16040493"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Visa, C., Rodriguez, R., Rinc\u00f3n, \u00c1., Pe\u00f1a, S., Serrano, D.R., and Torrado, J.J. (2025). Understanding the impact of sustainable pharmaceutical packaging on the chemical stability of silodosin. Pharmaceutics, 17.","DOI":"10.20944\/preprints202510.1889.v1"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F., Zhang, Z., Li, Y., and Huang, W. (2022). Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122682"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Swetha, K., Kotla, N.G., Tunki, L., Jayaraj, A., Bhargava, S.K., Hu, H., Bonam, S.R., and Kurapati, R. (2023). Recent advances in the lipid nanoparticle-mediated delivery of mRNA vaccines. Vaccines, 11.","DOI":"10.20944\/preprints202302.0142.v1"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"113559","DOI":"10.1016\/j.jconrel.2025.02.055","article-title":"Investigating the stability of RNA-lipid nanoparticles in biological fluids: Unveiling its crucial role for understanding LNP performance","volume":"381","author":"Zhang","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"101596","DOI":"10.1016\/j.omtm.2025.101596","article-title":"Structuring of lipid nanoparticle mRNA formulations at acidic and neutral pH: X-ray scattering and molecular dynamics studies","volume":"33","author":"Guruge","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e2309472120","DOI":"10.1073\/pnas.2309472120","article-title":"Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"18440","DOI":"10.1021\/jp303267y","article-title":"Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core","volume":"116","author":"Leung","year":"2012","journal-title":"J. Phys. Chem. C"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1016\/j.bpj.2022.08.037","article-title":"mRNA lipid nanoparticle phase transition","volume":"121","author":"Trollmann","year":"2022","journal-title":"Biophys. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2342592","DOI":"10.1080\/21645515.2024.2342592","article-title":"Long-term stability and immunogenicity of lipid nanoparticle COVID-19 mRNA vaccine is affected by particle size","volume":"20","author":"Shi","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"30371","DOI":"10.1021\/acsami.2c06065","article-title":"Nucleic acid-loaded lipid nanoparticle interactions with model endosomal membranes","volume":"14","author":"Spadea","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e2404555121","DOI":"10.1073\/pnas.2404555121","article-title":"Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments","volume":"121","author":"Garaizar","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1038\/s41467-025-63651-4","article-title":"Buffer optimization of siRNA-lipid nanoparticles mitigates lipid oxidation and RNA-lipid adduct formation","volume":"16","author":"Estabrook","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.molpharmaceut.2c00010","article-title":"Current status and future perspectives on mRNA drug manufacturing","volume":"19","author":"Webb","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Gote, V., Bolla, P.K., Kommineni, N., Butreddy, A., Nukala, P.K., Palakurthi, S.S., and Khan, W. (2023). A comprehensive review of mRNA vaccines. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032700"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jconrel.2024.07.052","article-title":"Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings","volume":"373","author":"Fan","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.xphs.2022.11.001","article-title":"The storage and in-use stability of mRNA vaccines and therapeutics: Not a cold case","volume":"112","author":"Nilsson","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"19590","DOI":"10.1038\/s41598-024-70680-4","article-title":"Impact of mixing and shaking on mRNA-LNP drug product quality characteristics","volume":"14","author":"Matthessen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/15476286.2024.2333123","article-title":"mRNA vaccine designs for optimal adjuvanticity and delivery","volume":"21","author":"Mochida","year":"2024","journal-title":"RNA Biol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1016\/j.xphs.2024.12.013","article-title":"Recent advances in drying and development of solid formulations for stable mRNA and siRNA lipid nanoparticles","volume":"114","author":"Arte","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Alejo, T., Toro-C\u00f3rdova, A., Fern\u00e1ndez, L., Rivero, A., Stoian, A.M., P\u00e9rez, L., and de Miguel, D. (2024). Comprehensive optimization of a freeze-drying process, achieving enhanced long-term stability and in vivo performance of lyophilized mRNA-LNPs. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms251910603"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Bhujel, R., Enkmann, V., Burgstaller, H., and Maharjan, R. (2025). Artificial intelligence-driven strategies for targeted delivery and enhanced stability of RNA-based lipid nanoparticle cancer vaccines. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080992"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Youssef, M., Hitti, C., Puppin Chaves Fulber, J., and Kamen, A.A. (2023). Enabling mRNA therapeutics: Current landscape and challenges in manufacturing. Biomolecules, 13.","DOI":"10.3390\/biom13101497"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Knezevic, I., Liu, M.A., Peden, K., Zhou, T., and Kang, H.N. (2021). Development of mRNA vaccines: Scientific and regulatory issues. Vaccines, 9.","DOI":"10.3390\/vaccines9020081"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/22221751.2022.2026742","article-title":"WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20\u201322 April 2021","volume":"11","author":"Liu","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Saxena, T., Sharvani, A., Stavika, A., and Rohini, M. (2025). Regulatory considerations for messenger RNA vaccines: A comprehensive review on World Health Organization guidelines on development, production, and clinical evaluation. Perspect. Clin. Res.","DOI":"10.4103\/picr.picr_199_25"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Banoun, H. (2023). mRNA: Vaccine or gene therapy? The safety regulatory issues. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310514"},{"key":"ref_169","first-page":"1","article-title":"Challenges faced by states and the WHO in efficiently regulating the use of mRNA vaccines","volume":"21","author":"Bouderhem","year":"2024","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_171","unstructured":"WHO (2021). Executive Summary WHO Informal Consultation on Regulatory Considerations for Evaluation of the Quality, Safety and Efficacy of RNA-Based Prophylactic Vaccines for Infectious Diseases, WHO."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1377\/hlthaff.2020.01620","article-title":"An overview of vaccine development, approval, and regulation, with implications for COVID-19","volume":"40","author":"Kesselheim","year":"2021","journal-title":"Health Aff."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cpt.2828","article-title":"Safety monitoring of COVID-19 vaccines: Perspective from the European Medicines Agency","volume":"113","author":"Durand","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"101700","DOI":"10.1016\/j.biologicals.2023.101700","article-title":"Regulatory perspective for quality evaluation of lipid nanoparticle-based mRNA vaccines in China","volume":"84","author":"Lu","year":"2023","journal-title":"Biologicals"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Kis, Z., Kontoravdi, C., Shattock, R., and Shah, N. (2021). Resources, production scales and time required for producing RNA vaccines for the global pandemic demand. Vaccines, 9.","DOI":"10.3390\/vaccines9010003"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Fatima, M., An, T., and Hong, K.J. (2025). Revolutionizing mRNA vaccines through innovative formulation and delivery strategies. Biomolecules, 15.","DOI":"10.3390\/biom15030359"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Buschmann, M.D., Carrasco, M.J., Alishetty, S., Paige, M., Alameh, M.G., and Weissman, D. (2021). Nanomaterial delivery systems for mRNA vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9010065"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Khan, M.D.F.H., Baudin, F., Sudalaiyadum Perumal, A., and Kamen, A.A. (2025). Freeze-drying of mRNA-LNPs vaccines: A review. Vaccines, 13.","DOI":"10.20944\/preprints202507.1044.v1"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Nomani, A., Saraswat, A., Brown, H., Kuo, J.C., Duong, H.T.T., Wu, J., Zhang, Y., Fu, Y., Moon, Y., and Wahidi, S. (2026). Identifying key factors affecting mRNA-lipid nanoparticles drug product formulation stability. Nanomaterials, 16.","DOI":"10.3390\/nano16040268"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s42004-025-01699-5","article-title":"Spotlighting the criticality of lipid quality control through a mechanistic investigation of mRNA activity loss in lipid nanoparticles","volume":"8","author":"Kang","year":"2025","journal-title":"Commun. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1016\/j.xphs.2024.09.005","article-title":"Current state of nanomedicine drug products: An industry perspective on outstanding CMC challenges","volume":"113","author":"Clogston","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"ref_183","unstructured":"World Health Organization (WHO) (2022). Evaluation of the Quality, Safety and Efficacy of Messenger RNA Vaccines for the Prevention of Infectious Diseases: Regulatory Considerations, WHO."},{"key":"ref_184","unstructured":"European Medicines Agency (EMA) (2025). Draft Guideline on the Quality Aspects of mRNA Vaccines, EMA. EMA\/CHMP\/BWP\/82416\/2025."},{"key":"ref_185","unstructured":"EDQM (2025). European Pharmacopoeia Commission Adopts First Three General Texts on mRNA Vaccines (5.36, 5.39, 5.40), Council of Europe."},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Skerritt, J.H. (2025). Considerations for mRNA product development, regulation and deployment across the lifecycle. Vaccines, 13.","DOI":"10.20944\/preprints202502.1111.v1"},{"key":"ref_187","unstructured":"U.S. Food and Drug Administration (FDA) (2024). Platform Technology Designation Program for Drug Development: Draft Guidance for Industry, FDA."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s13023-025-04038-y","article-title":"Perspectives on the FDA platform technology designation program for the approval of gene therapies: A Swiss multi-stakeholder exploratory interview study","volume":"20","author":"Han","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_189","unstructured":"International Council for Harmonisation (ICH) (2019). ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, ICH."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"101454","DOI":"10.1016\/j.omtm.2025.101454","article-title":"Characterization of intact mRNA-based therapeutics by charge detection mass spectrometry and mass photometry","volume":"33","author":"Barnes","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41467-024-45666-5","article-title":"Liquid crystalline inverted lipid phases encapsulating siRNA enhance lipid nanoparticle mediated transfection","volume":"15","author":"Pattipeiluhu","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e70013","DOI":"10.1002\/ansa.70013","article-title":"Current PAT landscape in the downstream processing of biopharmaceuticals","volume":"6","author":"Sathiyapriyan","year":"2025","journal-title":"Anal. Sci. Adv."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"124251","DOI":"10.1016\/j.ijpharm.2024.124251","article-title":"Raman and NIR spectroscopy-based real-time monitoring of the membrane filtration process of a recombinant protein for the diagnosis of SARS-CoV-2","volume":"660","author":"Vasko","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Rodriguez-Loya, J., Lerma, M., and Gardea-Torresdey, J.L. (2023). Dynamic light scattering and its application to control nanoparticle aggregation in colloidal systems: A review. Micromachines, 15.","DOI":"10.3390\/mi15010024"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"125322","DOI":"10.1016\/j.ijpharm.2025.125322","article-title":"Data-driven model predictive control for continuous pharmaceutical manufacturing","volume":"672","author":"Diangelakis","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_196","first-page":"8204","article-title":"Digital twin fundamentals of mRNA in vitro transcription in variable scale toward autonomous operation","volume":"9","author":"Hengelbrock","year":"2024","journal-title":"ACS Omega"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"126301","DOI":"10.1016\/j.ijpharm.2025.126301","article-title":"End-to-end digital twin software for continuous mRNA manufacturing","volume":"686","author":"Shahab","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s42256-022-00571-8","article-title":"Deep learning models for predicting RNA degradation via dual crowdsourcing","volume":"4","author":"Kladwang","year":"2022","journal-title":"Nat. Mach. Intell."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","article-title":"Algorithm for optimized mRNA design improves stability and immunogenicity","volume":"621","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41565-025-01975-4","article-title":"Designing lipid nanoparticles using a transformer-based neural network","volume":"20","author":"Chan","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41541-021-00322-7","article-title":"Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases","volume":"6","author":"Kis","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"15533","DOI":"10.1038\/s41598-025-99458-y","article-title":"Bayesian hierarchical model predicts biopharmaceutical stability indicators and shelf life with application to multivalent human papillomavirus vaccine","volume":"15","author":"Ferrari","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Schnetzinger, F., Cl\u00e9net, D., Gilbert, P.A., Guzzi, A., Paludi, M., Weusten, J., and Hesselink, R. (2024). Stability preparedness: The not-so-cold case for innovations in vaccine stability modelling and product release. Vaccines, 12.","DOI":"10.3390\/vaccines12091000"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Bourderi-Cambon, A., Fadhlaoui, K., Garrait, G., Lain\u00e9, E., Dhifallah, I., Rossano, M., Caisse, P., and Beyssac, E. (2025). Improving in vitro\u2013in vivo correlation (IVIVC) for lipid-based formulations: Overcoming challenges and exploring opportunities. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17101310"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1021\/acs.nanolett.8b00432","article-title":"A direct comparison of in vitro and in vivo nucleic acid delivery mediated by hundreds of nanoparticles reveals a weak correlation","volume":"18","author":"Paunovska","year":"2018","journal-title":"Nano Lett."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e25076","DOI":"10.1002\/adfm.202525076","article-title":"PRELIVE: A framework for predicting lipid nanoparticles in vivo efficacy and reducing reliance on animal testing","volume":"36","author":"Hanafy","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"123942","DOI":"10.1016\/j.ijpharm.2024.123942","article-title":"Understanding the in vitro\u2013in vivo nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin","volume":"654","author":"Gan","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1007\/s13346-024-01646-2","article-title":"Toward an international standardisation roadmap for nanomedicine","volume":"14","author":"Caputo","year":"2024","journal-title":"Drug Deliv. Transl. Res."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/790\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:50:24Z","timestamp":1782809424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/7\/790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":208,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["pharmaceutics18070790"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18070790","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]}}}